ACUTA CAPITAL PARTNERS, LLC
Long book
$140.6M
Q1 2026
Positions
26
Top-10 weight
78%
concentration
Last quarter
+8.7%
SPY +14.8%
Turnover
40%
of book per quarter
Strategy in plain words
auto-generated from filingsACUTA CAPITAL PARTNERS, LLC is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $140.6M US long book across 26 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: PRAXIS PRECISION MEDICINES I, TERNS PHARMACEUTICALS INC, WHITEHAWK THERAPEUTICS INC, TANGO THERAPEUTICS INC, BRIGHT MINDS BIOSCIENCES INC.
Over the last 9 quarters its long book ran on average 3.5pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-9.7%
Q2 2024
+14.6%
Q3 2024
-9.2%
Q4 2024
-18.5%
Q1 2025
+3.1%
Q2 2025
+30.9%
Q3 2025
+42.9%
Q4 2025
+9.3%
Q1 2026
+8.7%
Sector allocation
Healthcare 81%
Other 19%
Long book by quarter
What does ACUTA CAPITAL own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 84.9K | $27.4M | 19.5% | +2.2% |
| 430 TERNS PHARMACEUTICALS INC | — | 495.8K | $26.1M | 18.6% | -22.2% |
| WHWK WHITEHAWK THERAPEUTICS INC | Healthcare | 3.4M | $11.8M | 8.4% | Held |
| TNGX TANGO THERAPEUTICS INC | Healthcare | 441.8K | $9.2M | 6.6% | +56.3% |
| DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 112.0K | $8.2M | 5.8% | +32.6% |
| STRO SUTRO BIOPHARMA INC | Healthcare | 269.4K | $6.7M | 4.8% | +299.4% |
| ERAS ERASCA INC | Healthcare | 354.6K | $5.7M | 4.1% | New |
| SRZN SURROZEN INC | Healthcare | 172.8K | $5.0M | 3.6% | -3.1% |
| OCUL OCULAR THERAPEUTIX INC | Healthcare | 592.1K | $5.0M | 3.6% | -43.8% |
| CMPX COMPASS THERAPEUTICS INC | Healthcare | 849.1K | $4.5M | 3.2% | -22.3% |
| NERV MINERVA NEUROSCIENCES INC | Healthcare | 709.5K | $4.3M | 3.0% | Held |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 191.8K | $3.6M | 2.5% | +223.5% |
| OCS OCULIS HOLDING AG | Healthcare | 98.3K | $2.6M | 1.9% | -3.4% |
| RVMD REVOLUTION MEDICINES INC | Healthcare | 26.1K | $2.5M | 1.8% | +209.9% |
| FDMT 4D MOLECULAR THERAPEUTICS INC | Healthcare | 242.3K | $2.3M | 1.6% | New |
| AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 151.1K | $2.1M | 1.5% | -54.7% |
| TSHA TAYSHA GENE THERAPIES INC | Healthcare | 439.5K | $2.0M | 1.4% | -3.4% |
| IDYA IDEAYA BIOSCIENCES INC | Healthcare | 48.2K | $1.6M | 1.1% | New |
| DSGN DESIGN THERAPEUTICS INC | Healthcare | 145.9K | $1.6M | 1.1% | -3.3% |
| UTHR UNITED THERAPEUTICS CORP | Healthcare | 2.2K | $1.3M | 0.9% | -3.1% |
| TRDA ENTRADA THERAPEUTICS INC | Healthcare | 89.4K | $1.1M | 0.8% | New |
| AVTX AVALO THERAPEUTICS INC | Healthcare | 60.8K | $908K | 0.6% | New |
| LBRX LB PHARMACEUTICALS INC | Healthcare | 28.9K | $713K | 0.5% | -3.6% |
| MAZE MAZE THERAPEUTICS INC | Healthcare | 19.3K | $577K | 0.4% | -3.3% |
| UNCY UNICYCIVE THERAPEUTICS INC | Healthcare | 58.0K | $381K | 0.3% | -3.4% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 27 | $141.8M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 30 | $147.3M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 28 | $96.8M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 28 | $71.6M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 34 | $86.2M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 39 | $99.4M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 41 | $123.5M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 33 | $118.7M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 33 | $153.9M | canonical | SEC ↗ |